翔宇医疗(688626) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥135,635,534.31, representing a year-over-year increase of 1.09%[6] - The net profit attributable to shareholders for Q3 2022 was ¥52,906,099.84, showing a significant increase of 17.34% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥30,186,272.16, reflecting a decrease of 20.21% year-over-year[10] - The basic and diluted earnings per share for Q3 2022 were both ¥0.33, a decline of 33.33% compared to the previous year[10] - Total operating revenue for the first three quarters of 2022 reached CNY 356,526,790.54, a slight increase from CNY 350,974,556.35 in the same period of 2021[34] - Net profit for the third quarter of 2022 was CNY 90,251,261.58, down from CNY 130,505,114.47 in the previous year[36] - Earnings per share for the third quarter were CNY 0.58, compared to CNY 0.87 in the same quarter of 2021[39] Assets and Liabilities - The company's total assets at the end of Q3 2022 amounted to ¥2,198,974,328.70, a slight increase of 0.75% from the end of the previous year[10] - The total liabilities increased to CNY 292,159,566.78 from CNY 236,967,892.99 year-on-year[34] - The total equity decreased to CNY 1,906,814,761.92 from CNY 1,945,581,842.01 year-on-year[34] - The total equity attributable to shareholders decreased by 2.07% to ¥1,895,032,614.31 compared to the end of the previous year[10] Cash Flow - The company reported a net cash flow from operating activities of ¥89,377,803.45, which increased by 25.03% year-to-date[10] - In the first three quarters of 2022, the net cash flow from operating activities was ¥89,377,803.45, an increase of 25% compared to ¥71,487,504.46 in the same period of 2021[44] - Cash inflow from operating activities totaled ¥520,332,766.72, up from ¥448,259,097.88 in the previous year, reflecting a growth of approximately 16%[44] - The cash outflow from operating activities increased to ¥430,954,963.27 from ¥376,771,593.42, representing a rise of about 14%[44] - The company reported a net cash flow from financing activities of -¥124,338,824.46, contrasting with a positive cash flow of ¥943,116,905.55 in the previous year[47] - The ending balance of cash and cash equivalents was ¥721,936,846.52, down from ¥768,332,442.15 at the end of the previous year[47] Research and Development - Research and development expenses totaled ¥22,548,559.49 for Q3 2022, an increase of 37.45% year-over-year, accounting for 16.62% of operating revenue[10] - Research and development expenses for the first three quarters of 2022 were CNY 66,082,833.18, up from CNY 45,656,969.46 in the previous year[34] - The company plans to continue optimizing its R&D personnel structure and increasing investment in R&D activities to drive future growth[12] Intellectual Property and Innovation - The company obtained 14 new medical device registration certificates, bringing the total to 236[21] - A total of 77 new patents were granted, increasing the cumulative total to 1,278[21] - The company has a total of 2,206 intellectual property applications, with 1,534 granted[24] - The company was recognized as a "National Technology Innovation Demonstration Enterprise" in 2022[23] - The company led the establishment of an industrial internet cloud platform for rehabilitation medical equipment, which was officially recognized by the Henan provincial expert group[23] - The company received the first prize in the "Technology Innovation Award" from the China Rehabilitation Medical Association for a project on key rehabilitation diagnostic equipment[23] Other Financial Metrics - Cash and cash equivalents decreased from ¥829,615,619.99 in 2021 to ¥724,592,013.03 in 2022[26] - The company’s inventory increased from ¥159,404,577.05 in 2021 to ¥204,166,479.46 in 2022[29] - The company’s long-term equity investments increased from ¥16,714,698.99 in 2021 to ¥18,661,676.59 in 2022[29] - Deferred income increased to CNY 63,783,548.77 from CNY 53,723,412.32 year-on-year[34] - The company reported a financial expense of CNY -19,290,438.51, compared to CNY -15,140,697.15 in the previous year[36] - Investment income for the third quarter was CNY 10,640,535.89, significantly higher than CNY 5,813,168.24 in the same period last year[36] - Employee compensation payments rose to ¥139,586,947.02 from ¥110,932,348.93, reflecting an increase of about 26%[44] - The cash received from tax refunds increased to ¥6,232,785.59 from ¥3,798,020.33, showing a growth of approximately 64%[44]